Cabell Eysmans

Phase I/II trial of PD-1 antibody nivolumab with peptide vaccine in patients naive to or that failed ipilimumab.

G. Gibney, J. Weber, R. Kudchadkar, 2013 .

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma.

C. Horak, G. Gibney, H. Inzunza, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma

C. Horak, M. Schell, G. Gibney, 2014, Clinical Cancer Research.

Clinical Safety , CorrelativeMarkers , andClinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma

C. Horak, M. Schell, G. Gibney, 2015 .

Safety and efficacy of adjuvant anti-PD1 therapy (nivolumab) in combination with vaccine in resected high-risk metastatic melanoma.

G. Gibney, J. Weber, R. Kudchadkar, 2013 .